Skip to main content

Advertisement

Table 2 Factors and prognosis of patients with LPA by Univariate Analysis

From: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma

Factors n 5-year survival (%) p
Sex    
 Male 30 54.73 0.7494
 Female 51 46.43  
Smoking    
 No 53 56.39 0.1286
 yes 28 40.56  
Proportion of lepidic growth (BAC) in adenocarcinoma*    
 ≤50% (including 0%) 50 35.69 0.0375
 >50% 31 58.32  
Age    
 ≤60 years 25 52.85 0.6028
 >60 years 56 47.74  
Location    
 Central 7 42.86 0.2521
 Peripheral 74 50.47  
Staging    
 I 50 69.87 0.0002
 II 26 38.46  
 III 5 15.63  
T stage    
 T1 43 60.63 0.0142
 ≥T2 38 43.38  
N stage    
 N0 62 63.20 0.0004
 N1 16 38.46  
 N2 3 15.63  
Surgical procedure    
 Lobectomy 79 53.85  
 Pneumonectomy 2 49.12  
Laterality    
 Left 38 52.12 0.2873
 Right 43 48.29  
ECOG performance status    
 0 75 50.83 0.4872
 1 6 49.15  
Histologic differentiation    
 Well 58 60.37 0.0089
 Moderate/poorly 23 41.28  
Claudin 1    
 - 33 26.75 0.0034
 + 48 63.20  
c-fos    
 - 28 55.19 0.8438
 + 53 29.43  
Claudin 10    
 - 25 30.30 0.0019
 + 56 59.75  
MMP-2    
 - 19 12.00 0.3208
 + 62 41.81  
Combination of CLDN1&CLDN10    
 both factors expressed 35 68.90 0.0000
 either factor expressed 35 44.32  
 neither factor expressed 11 0  
  1. *: We defined 50% as a cutoff for lepidic growth in these tumors because some studies showed that if the lepidic growth was more than 50%, the 5-year survival of patients with T1 lung adenocarcinoma was much better than those with less than 50% lepidic growth [69].